Answers are grounded in this paper and cite their sources.
Quillaic acid is the aglycone of QS-21, a triterpenoid saponin that has been clinically evaluated as an immunoadjuvant. Current access to quillaic acid has so far been limited to isolation from natural sources or semisynthesis from minimally-oxidized oleanane precursors, which limits the range of modifications that can be performed on the pentacyclic skeleton. In the same vein, previous total syntheses of oleanane triterpenoids have largely relied on cascade polyene cyclization, which will be difficult to implement on quillaic acid due to its functional group arrangements. We disclose here a convergent annulation strategy to synthesize quillaic acid. Key features of the synthesis include a formal annulation of two key building blocks by way of Utimoto coupling and metal-hydride hydrogen atom transfer (MHAT) cyclization, and generation of the A/B-ring fragment via enzymatic C–H oxidation of a dehydroabietic acid-derived precursor. The versatility of the route is further showcased through the synthesis of a novel analogue bearing a five-membered E-ring.
No takes yet. Share an insight, caveat, or question.
Qiao et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: